Serologic screening before endoscopy: The value of Helicobacter pylori serology, serum recognition of the CagA and VacA proteins, and serum pepsinogen I

Scandinavian Journal of Gastroenterology

Volumn 34, Issue 9, 1999, Pages 856-863

  Bodger, K ^a   Wyatt, J I ^a   Heatley, R V ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

CagA protein; Dyspepsia; Endoscopy; Helicobacter pylori; Pepsinogen I; VacA protein; Western blotting

Indexed keywords

BACTERIAL PROTEIN; PEPSINOGEN I; VIRULENCE FACTOR;

ADULT; ARTICLE; BACTERIAL INFECTION; BACTERIAL VIRULENCE; DYSPEPSIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTRITIS; HELICOBACTER PULLORUM; HUMAN; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PEPTIC ULCER; PRIORITY JOURNAL; SCREENING TEST; SERODIAGNOSIS;

ADULT; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BLOTTING, WESTERN; DYSPEPSIA; ENDOSCOPY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PEPSINOGEN A; RADIOIMMUNOASSAY; STATISTICS, NONPARAMETRIC;

EID: 0032887735     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655299750025309     Document Type: Article

References (46)

1. Working Party of the Clinical Services Committee of the British Society of Gastroenterology. Provision of gastrointestinal endoscopy and related services for a district general hospital. Gut 1991;32:95-105.
2. Gear MWL, Wilkinson SP, Open access upper alimentary endoscopy. Br J Hosp Med 1989;41:438-44.
3. Williams B, Luckas M, Ellingham JHM, Dain A, Wicks AC. Do young patients with dyspepsia need investigation? Lancet 1988;2:1349-51.
4. Bodger K, Daly MJ, Heatley RV. Clinical economics review: Helicobacter pylori-associated peptic ulcer disease. Aliment Pharmacol Ther 1997;11:273-82.
5. Christie J, Shepherd NA, Codling BW, Valori RM. Gastric cancer below the age of 55: implications for screening patients with uncomplicated dyspepsia. Gut 1997;41:513-7.
6. Sobala GM, Crabtree JE, Pentith JA, Rathbone BJ, Shalleross TM, Wyatt JI, el al. Screening dyspepsia by serology to Helicobacter pylori. Lancet 1991;338:94-6.
7. Mendall MA, Goggin PM, Marrero JM. Role of Helicobacter pylori serology in screening prior to endoscopy. Eur J Gastroenterol Hepatol 1992;4:713-7.
8. Patel P. Mendall MA, Khulusi S, Molineux N, Levy J, Maxwell JD, et al. Salivary antibodies to Helicobacter pylori: screening dyspeptic patients before endoscopy. Lancet 1994;344:511-2.
9. Vyas SK, Sharpstone D. Treasure J. Fine D, Hawtin PR. Pre-endoscopy screening using serodiagnosis of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1994;6:783-5.
10. Patel P, Khulusi S. Mendall MA, Lloyd R, Jazrawi R, Maxwell JD, et al. Prospective screening of dyspeptic patients by H. pylori serology. Lancet 1995;346:1315-8.
11. Mendall MA, Jazrawi RP, Marrero JM, Mulineux N, Levy J, Maxwell JD, et al. Serology for Helicobacter pylori compared with symptom questionnaires in screening before direct access endoscopy. Gut 1995;36:330-3.
12. British Society of Gastroenterology. Dyspepsia management guidelines, In: BSG guidelines in gastroenterology. London: BSG; 1996.
13. Atherton JC. The clinical relevance of strain types of Helicobacter pylori. Gut 1997;40:701-3.
14. Cover TL, Glupezynski Y, Lage AP, Burette A, Tummuru MK, Perez-Perez GI, et al, Serologic detection of infection with cagA+ Helicobacter pylori strains. J Clin Microbiol 1995;33: 1496-500.
15. Crabtree JE, Taylor JD, Wyatt JI, Heatley RV, Shalleross TM, Thompkins DS, et al. Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration, and gastric pathology. Lancet 1991;338:332-5.
16. Peek RM Jr. Miller GG, Tham KT, Perez-Penez GI, Zhuo X, Atherton JG, et al. Heightened inflammatory response and cytokine expression in vivo to cugA+ Helicobacter pylori strains. Lab Invest 1995:73:760-70.
17. Ching CK, Wong BC, Kwok E., Ong L, Covacci A, Lam SK. Prevalence of CagA-bearing Helicobacter pylori strains detected by the anti-CagA assay in patients with peptic ulcer disease and in controls. Am J Gastroenterol 1996;91:949-53.
18. Kuipers EJ, Perez-Perez. GI, Meuwissen SG, Blaser MJ. Helicobacter pylori and atrophic gastrilis: importance of the cagA status, J Natl Cancer Inst 1995;87:1777-80.
19. Blaser MJ, Perez-Perez GI, Kleanthous H, Cover TL, Peek RM, Chyou PH, et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 1995;55:211-5.
20. Parsonnet J, Friedman GD, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative H. pylori infection. Gut 1997;40:297-301.
21. Atherton JC. H. pylori virulence factors. Br Med Bull 1998;54: 105-20.
22. Rautelin H, Blumberg B, Jarnerot G, Danielson D. Nonopsonic activation of neutrophils and cytotoxin production by Helicobacter pylori: ulcerogenic markers. Scand J Gastroenterol 1994;29:128-32.
23. Tee W, Lambert JR. Dwyer B. Cytotoxin production by Helicobacter pylori from patients with upper gastrointestinal tract diseases. J Clin Microbiol 1995;33:1203-5.
24. Fox JG, Correa P, Taylor NS, Thompson N, Fontham F, Janney F, et al. High prevalence and persistence of cylotoxin-positive Helicobacter pylori strains in a population with a high prevalence of atrophic gastritis. Am J Gastroenterol 1992;87:1554-60.
25. Trier JS. Morphology of the gastric mucosa in patients with ulcer diseases. Am J Dig Dis 1979;21:138-40.
26. Correa P. Chronic gastritis: a clinico-pathologic classification. Am J Gastroenterol 1988;83:504-9.
27. Samloff IM, Varis K, Ihamaki T, Siurala M. Rotter JI. Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. Gastroenterology 1982;83: 204-9.
28. Kreuning J, Lindeman J, Biedmond I, Lamers CBHW. Serological parameters in assessment of degree of gastritis in healthy volunteers. Dig Dis Sci 1995:609-14.
29. Samloff JM, Liebman WM. Panitch NM. Serum group I pepsinogens by radioimmunassay in control subjects and patients with peptic ulcer. Gastroenterology 1975;69:83-90.
30. Kekki M, Samloff IM, Varis K, Jhamäki T. Serum pepsinogen I and serum gastrin in the screening of severe atrophic corpus gastritis. Scand J Gastroenterol 1991;26 Suppl 186:109-16.
31. Webb PM, Hengels KJ, Moller H, Newell DG, Palli D, Elder JB, et al. The epidemiology of low serum pepsjnogen I levels and an international association with gastric cancer rules. Gastroenterology 1994;107:1335-43.
32. Mitchell HM, Hazell SL, Li YY, Hu PJ. Serological response to specific Helicobacter pylori antigens: antibody against CagA antigen is not predictive of gastric cancer in a developing country. Am J Gastroenterol 1996;91:1785-8.
33. Feldman RA, Decks JJ, Evans SJW. Multi-laboratory comparison of eight commercially available Helicobacter pylori serology kits. Eur J Clin Microbiol Infect Dis 1995;14:428-33.
34. Wilcox WH, Dent TH, Hunter JO, Gray JJ, Brown DF, Wight DG, et al. Accuracy of serology for the diagnosis of Helicobacter pylori infection-a comparison of eight kits. J Clin Pathol 1996;49:373-6.
35. Figura N, Oderda G, Verdani S. Evaluation of a commercial ELISA kit for the serological diagnosis of Helicobacter pylori infection. New Microbiol 1994; 17:319-25.
36. Maconi G, Vugo L, Galletta G. Imbesi V, Sangaletti O, Parente F, et al. Is routine histological evaluation an accurate test for Helicobacter pylori infection. Aliment Pharmacol Ther 1999; 13: 327-31.
37. MCColl KEL, El-Nujumi A, Murray L, El-Omar H, Gillen D, Dickson A. et al. The Helicobacter pylori breath test: a surrogate marker for peptic ulcer disease in dyspeptic patients. Gut 1997;40:302-6.
38. Cover TL, Cao P, Lind CD, Tham KT, Blaser MJ. Correlation between vacuolating cytotoxin production by Helicobacter pylori isolates in vitro and in vivo. Infect Immun 1993;61: 5008-12.
39. Perez-Perez GI, Tham KT, Peek RM, Atherton JC, Blaser MJ, Cover JL. Serologic responses to type m1 and m2 H. pylori VacA antigens. Gut 1997;41:A110.
40. Chang FY, Cheng JT, Lee FY, Wang TF, Lai KH, Lee SD, et al. Serum pepsinogen I levels in patients with non-ulcer dyspepsia, J Gastroenterol Hepatol 1990;5:271-6.
41. Knight T, Wyatt J, Wilson A. Greaves S, Newell D, Hengels K, Corbett M, et al. H. pylori gastritis and serum pepsinogen levels in a healthy population: development of a biomarker strategy for gastric atrophy in high risk groups, Br J Cancer 1996;73:819-24.
42. Parsonnet J, Samloff IM, Nelson LM, Orentreich N, Vogelman JH, Friedman GD. Helicobacter pylori, pepsinogen, and risk for gastric adenocarcinoma. Cancer Epidemiol Biomarkers Prevent 1993;2:461-6.
43. Goodbourn C, Teare EL, Saverymuttu S, Khin C. Pre-endoscopy screening for Helicobacter [letter]. Lancet 1996:347:699-700.
44. Dodger K, Daly MJ, Heatley RV. Dyspepsia workload in primary care. Gut 1996:39 Suppl 1:A1.
45. Bytzer P, Hansen JM, Schaffalitzky de Muckadell OB. Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia. Lancet 1994;343:811-6.
46. Hungin APS, Thomas PR, Bramble MG, Corbett WA, Idle N, Contractor BR, el al. What happens to patients following open access gastroscopy? An outcome study from general practice. Br J Gen Pract 1994:44:519-21.